US FDA approves Hemofarm's methylprednisolone product
This article was originally published in Scrip
Executive Summary
Hemofarm, Stada's subsidiary in Serbia, has received a production and marketing certificate for two injectable formulations of methylprednisolone from the US FDA. The company, which exports its products to ex-Soviet republics, central Europe, Africa and the Middle East, claims to be the only company in the Balkans to have such a certificate.